Drug Trial Radar · NCT03673501
A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
453
Actual
Start
Feb 8, 2019
Primary completion
Sep 1, 2021
Study completion Dec 2027
Sponsor
- Lead sponsor
- Deciphera Pharmaceuticals, LLCIndustry
- Sponsor type
- Industry
- First posted
- Sep 17, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 2-arm, randomized, open-label, international, multicenter study comparing the efficacy of ripretinib to sunitinib in GIST patients who progressed on or were intolerant to first-line anticancer treatment with imatinib. Approximately 426 patients will be randomized in a 1:1 ratio to ripretinib 150 mg once daily (continuous dosing for 6 week cycles) or sunitinib 50 mg once daily (6 week cycles, 4 weeks on, 2 weeks off).
Conditions
- Gastrointestinal Stromal Tumors
Interventions
RipretinibDrug
Oral KIT/PDGFRA kinase inhibitor
SunitinibDrug
Oral receptor tyrosine kinase (RTK) inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) in the KIT Exon 11 Intent to Treat (ITT) PopulationTime frame: From date of randomization to earliest documented evidence of disease progression, or death due to any cause (up to 2.1 years)
- Progression Free Survival (PFS) in the All Patient (AP) Intent to Treat (ITT) PopulationTime frame: From date of randomization to earliest documented evidence of disease progression, or death due to any cause (up to 2.1 years)
Locations
121 sites in 22 countries. Site status is shown where the registry gives one.
Mayo Clinic Scottsdale
Scottsdale, Arizona
University of California San Diego Medical Center
La Jolla, California
UCLA Hematology Oncology Center - Main Site
Los Angeles, California
Stanford Medicine
Stanford, California
University of Colorado Hospital - Anschutz Cancer Pavillion
Aurora, Colorado
Rocky Mountain Cancer Centers
Denver, Colorado
Smilow Cancer Hospital at Yale
New Haven, Connecticut
Washington Cancer Institute at MedStar Washington Hospital Center
Washington D.C., District of Columbia
Mayo Clinic Florida
Jacksonville, Florida
Sylvester Comprehensive Cancer Center
Miami, Florida
Miami Cancer Institute at Baptist Health, Inc.
Miami, Florida
Orlando Health UF Health Cancer Center
Orlando, Florida
Moffitt Cancer Center
Tampa, Florida
Winship Cancer Institute
Atlanta, Georgia
Georgia Cancer Specialists
Sandy Springs, Georgia
Northwestern Memorial Hospital
Chicago, Illinois
University of Chicago Medical Center
Chicago, Illinois
IU Simon Cancer Center
Indianapolis, Indiana
University of Iowa Hospital and Clinics
Iowa City, Iowa
Norton Cancer Institute, Audubon Hospital Campus
Louisville, Kentucky
Johns Hopkins Hospital
Baltimore, Maryland
Dana Farber Cancer Institute
Boston, Massachusetts
Henry Ford Health System
Detroit, Michigan
University of Minnesota Medical Center-Fairview
Minneapolis, Minnesota
Mayo Clinic
Rochester, Minnesota
Washington University School of Medicine - Siteman Cancer Center
St Louis, Missouri
Rutgers Cancer Institute
New Brunswick, New Jersey
Roswell Park Cancer Institute
Buffalo, New York
The Monter Cancer Center
Lake Success, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Montefiore Medical Center-Montefiore Medical Park
The Bronx, New York
Duke University Medical Center
Durham, North Carolina
The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Solove Research Institute
Columbus, Ohio
University of Toledo
Toledo, Ohio
Stephenson Cancer Center
Oklahoma City, Oklahoma
Oregon Health & Science University Center for Health and Healing
Portland, Oregon
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Henry-Joyce Cancer Clinic
Nashville, Tennessee
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Dallas, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas
Showing 40 of 121 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.